GLOBAL NEWBORN SCREENING MARKET

1    Research Scope and Methodology
1.1    Report Scope
1.2    Research Methodology
1.3    Market Segmentation
1.4    Assumptions
1.5    Data and Prediction Modelling

2    Market Overview
2.1    Global Newborn Screening Market Overview (Addressable Market Size and Growth Potential), 2012-2016
2.2    Recent Historical Trends, 2013-2016
2.3    Global Newborn Screening Market, 2016
2.3.1    Key Market Development and Strategies
2.3.1.1    Mergers and Acquisition
2.3.1.2    Product Launch & Developments
2.3.1.3    Partnerships, Collaborations & Joint Ventures
2.3.1.4    Business Expansions and Contracts
2.3.2    Market Share Concentration
2.4    Technology Trends in Newborn Screening Market
2.5    Legal Requirements and Regulations
2.5.1    Regulatory Bodies
2.5.2    Consortia and Associations
2.6    Patent Analysis

3    Market Dynamics
3.1    Drivers
3.2    Challenges
3.3    Opportunities

4    Major Demand Determinants
4.1    Overview
4.2    Global Metabolic Disorders Statistics, 2016
4.2.1    Organic acid
4.2.1.1    Propionic acidemia (PROP)
4.2.1.2    Methylmalonic acidemia (methylmalonyl-CoA mutase, MUT)
4.2.1.3    Methylmalonic acidemia (cobalamin disorders; Cbl A, B)
4.2.1.4    Isovaleric academia (IVA)
4.2.1.5    Glutaric acidemia type I (GA1)
4.2.1.6    Others
4.2.2    Fatty Acid Oxidation
4.2.2.1    Carnitine uptake defect/carnitine transport defect (CUD)
4.2.2.2    Medium-chain acyl-CoA dehydrogenase deficiency (MCAD)
4.2.2.3    Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD)
4.2.2.4    Others
4.2.3    Amino acid
4.2.3.1    Argininosuccinic aciduria (ASA)
4.2.3.2    Citrullinemia, type I (CIT)
4.2.3.3    Maple syrup urine disease (MSUD)
4.2.3.4    Homocystinuria (HCY)
4.2.3.5    Others
4.3    Global Endocrine Disorders Statistics, 2016
4.4    Global Haemoglobin Disorders Statistics, 2016
4.5    Other Disorders Statistics, 2016

5    Global Newborn Screening Market Pricing Trends, 2013-2016
5.1    Overview
5.2    Metabolic Tests
5.3    Endocrine Tests
5.4    Haemoglobin Tests
5.5    Hearing Screen Test
5.6    Critical Congenital Heart Diseases (CCHD) Test
5.7    Others

6    Competitive Insights
6.1    Market Share Analysis, 2015 & 2016
6.2    Growth Share Matrix
6.2.1    By Test
6.2.2    By Country
6.2.3    By Technology
6.3    Comprehensive Competitive Index
6.4    Competitor Value Chain Analysis
6.5    Competitor Supply Chain Analysis
6.6    Competitor Brand-Value Matrix
6.7    Porter’s Five Force Analysis

8    Global Newborn Screening Market by Technology, 2016-2023 ($Million)
8.1    Overview
8.2    Tandem Mass Spectrometry
8.3    Electrophoresis
8.4    Enzymes and Immunoassays
8.5    DNA-based Assays
8.6    Pulse Oximetry Technology
8.7    Others

9    Global Newborn Screening Market by Condition, 2016-2023 ($Million)
9.1    Overview
9.2    Metabolic Disorders
9.2.1    Organic acid
9.2.1.1     Propionic acidemia (PROP)
9.2.1.2    Methylmalonic acidemia (methylmalonyl-CoA mutase, MUT)
9.2.1.3    Methylmalonic acidemia (cobalamin disorders; Cbl A, B)
9.2.1.4    Isovaleric academia (IVA)
9.2.1.5    Glutaric acidemia type I (GA1)
9.2.1.6    Others
9.2.2    Fatty Acid Oxidation
9.2.2.1    Carnitine uptake defect/carnitine transport defect (CUD)
9.2.2.2    Medium-chain acyl-CoA dehydrogenase deficiency (MCAD)
9.2.2.3    Very long-chain acyl-CoA dehydrogenase deficiency (VLCAD)
9.2.2.4    Others
9.2.3    Amino acid
9.2.3.1    Argininosuccinic aciduria (ASA)
9.2.3.2    Citrullinemia, type I (CIT)
9.2.3.3    Maple syrup urine disease (MSUD)
9.2.3.4    Homocystinuria (HCY)
9.2.3.5    Others
9.3    Endocrine disorders
9.3.1    Congenital hypothyroidism (CH)
9.3.2    Congenital adrenal hyperplasia (CAH)
9.4    Hemoglobin disorders
9.4.1    S,S disease (Sickle cell anemia) (Hb SS)
9.4.2    S, ßeta-thalassemia (Hb S/ßTh)
9.4.3    S,C disease (Hb S/C)
9.5    Other disorders
9.5.1    Biotinidase deficiency (BIOT)
9.5.2    Cystic fibrosis (CF)
9.5.3    Others

10    Global Newborn Screening Market by Product, 2016-2023 ($Million)
10.1    Overview
10.2    Instruments
10.3    Reagents
10.4    Other Consumables and Accessories

11    Global Newborn Screening Market by Region, 2016-2023 ($Million)
11.1    Overview
11.2    North America
11.2.1.    U.S.
11.2.2    Canada
11.3    Europe
11.3.1    Germany
11.3.2    U.K.
11.3.3    France
11.3.4    Italy
11.3.5    Spain
11.3.6    Rest of Europe (RoE)
11.4    Asia Pacific (APAC)
11.4.1    Japan
11.4.2    China
11.4.3    India
11.4.4    Rest of Asia Pacific (RoAPAC)
11.5    Rest of the World (RoW)

12    End-User Perception About Newborn Screening
12.1    Key Factors Influencing Decision About Newborn Screening Market
12.2    Influence of GPs, Labs, and KoLs on Decision Making
12.3    Innovation Trends of Newborn Screening Tests
12.4    Level of Competition among players
12.5    Willingness to Purchase Newborn Screening Tests/Kits
12.6    Perception About Pricing
12.7    Technology Preferences
12.8    Perception about Brand
12.9    Selection Criteria for Newborn Screening Tests
12.1    Sources of Information about Newborn Screening
12.11    Information Required to Purchase a new product
12.12    Any Unmet needs or Shortcoming with Market Available Newborn Screening Products
12.13    Preferred Channel for Purchasing

13    Company Profiles
13.1    PerkinElmer, Inc.
13.1.1    Company Overview
13.1.2    Product Profile
13.1.3    Financials
13.1.3.1     Financial Summary
13.1.4    Recent Developments & Strategies
13.1.5    SWOT Analysis
13.2    AB Sciex LLC (A Subsidiary of Danaher Corporation)
13.3    Drager
13.4    Waters Corporation
13.5    Smith’s Group
13.6    Fisher & Paykel Healthcare
13.7    Natus Medical Incorporated
13.8    Masimo Corporation
13.9    Agilent Technologies Inc.
13.10    Bio-Rad Laboratories, Inc.
13.11    Covidien PLC
13.12    GE Healthcare (A Subsidiary of General Electric Company)
13.13    Trivitron Healthcare
13.14    Snapshot of Other Key Players